H.C. Wainwright analyst Joseph Pantginis has reiterated their bullish stance on XOMA stock, giving a Buy rating on August 14.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Joseph Pantginis has given his Buy rating due to a combination of factors that highlight Xoma’s strategic maneuvers and financial performance. Xoma has been actively expanding its business model by acquiring companies and assets, which has bolstered its royalty portfolio. These acquisitions, including those of LAVA Therapeutics and HilleVax Inc., not only enhance Xoma’s asset base but also provide non-dilutive capital, strengthening its financial position.
Moreover, Xoma’s recent financial results have exceeded expectations, with second-quarter 2025 earnings per share surpassing estimates and revenues significantly higher than anticipated. The company’s revenue growth is driven by long-term royalty agreements from partnered assets, such as Vabysmo, Ojemda, and Miplyffa. These factors collectively underscore Xoma’s potential for sustained growth, justifying the Buy rating.
In another report released on August 14, Leerink Partners also maintained a Buy rating on the stock with a $55.00 price target.
Based on the recent corporate insider activity of 20 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of XOMA in relation to earlier this year.